Overview

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Status:
Recruiting
Trial end date:
2023-08-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed prior 12-week induction study AMAN (NCT03518086).
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Mirikizumab